In PRISM3, a multicenter, randomized, double-blind, placebo-controlled phase 2 trial, researchers assessed an investigational oral microbiome drug CP101 in 206 patients with recurrent C. difficle at 51 sites across the United States and Canada. The drug did meet the primary endpoint of sustained clinical cure among 74.5% of the patients with recurrent C. difficile who received a
Individuals with inflammatory bowel disease had a 4.1% increased incidence of dementia
